Actions of A-131701, a novel, selective antagonist for alpha-1a compared with alpha-1b adrenoceptors on intraurethral and blood pressure responses in conscious dogs and a pharmacodynamic assessment of in vivo prostatic selectivity
Pharmacological antagonism of α-adrenergic agonist induced increases in canine intraurethral pressure in vivo
Brune ME, Buckner SA, Polakowski J, Kerwin JF and Hancock AA (1995) Pharmacological antagonism of α-adrenergic agonist induced increases in canine intraurethral pressure in vivo. Drug Dev Res 34:267-275.
IV. International Union of Pharmacology nomenclature of adrenoceptors
Bylund DB, Eikenberg DC, Hieble JP, Langer SZ, Lefkowitz RJ, Minneman KP, Molinoff PB, Ruffolo Jr RR and Trendelenburg U (1994) IV. International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol Rev 46:121-136.
The use of α-adrenoceptor antagonists in the pharmacological management of benign prostatic hypertrophy: An overview
Hieble JP and Ruffolo, Jr RR (1996) The use of α-adrenoceptor antagonists in the pharmacological management of benign prostatic hypertrophy: An overview. Pharmacol Res 33:145-160.
Effect of alpha1 adrenoceptor antagonists on prostatic pressure and blood pressure in the anesthetized dog
Kenny BA, Naylor AM, Carter AJ, Read AM, Greengrass PM and Wyllie MG (1994) Effect of alpha1 adrenoceptor antagonists on prostatic pressure and blood pressure in the anesthetized dog. Urology 44:52-57.
A comparison of the binding and functional properties of alpha-1 adrenoceptors and area density of smooth muscle in the human, canine and rat prostates
Lepor H, Zhang W, Kobayashi S, Tang R, Wang B and Shapiro E (1994) A comparison of the binding and functional properties of alpha-1 adrenoceptors and area density of smooth muscle in the human, canine and rat prostates. J Pharmacol Exp Ther 270:722-727.
Doxazosin for benign prostatic hyperplasia: Long-term efficacy and safety in hypertensive and normotensive patients
Lepor H, Kaplan SA, Klimberg I, Mobley DF, Fawzy A, Gaffney M, Ice. K and Dias N (1997) Doxazosin for benign prostatic hyperplasia: Long-term efficacy and safety in hypertensive and normotensive patients. J Urol 157:525-530.
Comparison of hemodynamic effects of tamsulosin (TAM) and terazosin (TER) in man
Michel M, Schäfers RF, Fokuhl B, Wasmuth A and Schumacher H (1997) Comparison of hemodynamic effects of tamsulosin (TAM) and terazosin (TER) in man. J Urol 157:suppl. 137.
The Hytrin Community Assessment trial study: A one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia
Roehrborn CG, Oesterling JE, Auerbach S, Kaplan SA, Lloyd LK, Milam DE and Padley RJ (1996) The Hytrin Community Assessment trial study: A one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. Urology 47:159-168.
Assessment of the pharmacokinetic-pharmacodynamic interaction between terazosin and finasteride
Samara EE, Hosmane B, Locke C, Eason C, Cavanaugh J and Granneman GR (1996) Assessment of the pharmacokinetic-pharmacodynamic interaction between terazosin and finasteride. J Clin Phnrmacol 36:1169-1178.
Terazosin: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia
Wilde MI, Fitton A and Sorkin EM (1993) Terazosin: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drug Aging 3:258-277.
Tamsulosin: A review of its pharmacological properties and therapeutic potential in the management of symptomatic benign prostatic hypertrophy
Wilde MI and McTavish D (1996) Tamsulosin: A review of its pharmacological properties and therapeutic potential in the management of symptomatic benign prostatic hypertrophy. Drugs 52:883-898,
Relationships between pharmacokinetics and blockade of agonist-induced prostatic intra-urethral pressure and mean arterial pressure in the conscious dog after single and repeated daily oral administration of terazosin
Witte DG, Brune ME, Katwala SP, Milicic I, Kerwin Jr JF and Hancock AA (1997) Relationships between pharmacokinetics and blockade of agonist-induced prostatic intra-urethral pressure and mean arterial pressure in the conscious dog after single and repeated daily oral administration of terazosin. J Pharmacol Exp Ther 282:891-898.
Doxazosin: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension
Young RA and Brogden RN (1988) Doxazosin: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hyper- tension. Drugs 35:525-541.
